Characterization and dynamics of the soluble immunological microenvironment in melanoma patients undergoing radiotherapy

Michael Oertel¹*, Katrin Borrmann¹, Andrea Baehr², Hans Theodor Eich¹ and Burkhard Greve¹

Abstract

Background and purpose: Malignant melanoma constitutes an aggressive tumor of the skin, the pathogenesis of which is influenced by immunological processes. In this context, the influence of radiotherapy (RT) on inflammatory markers has not been studied in detail, yet.

Materials and methods: In this prospective analysis, 28 patients were recruited, 24 of these could be included for further analysis. According to protocol, patients underwent three blood-draws: before, after half of RT-fractions and after completion of RT. Serum levels of programmed death-ligand (PD-L) 1 and 2, interleukin 6 and cytotoxic t-lymphocyte-associated protein 4 were assessed via enzyme-linked immunosorbent assay and compared to healthy volunteers. Correlation with clinical data was attempted.

Results: Comparing patients with healthy volunteers, a significant difference in the mean baseline serum-level of PD-L1 (90.1 pg/ml vs. 76.7 pg/ml for patients vs. control, respectively; \( p = 0.024 \)) and PD-L2 (4.4 ng/ml vs. 8.7 ng/ml; \( p = 0.04 \)) could be found. Increased levels of PD-L1 were only found in patients with prior immunotherapy. There was a tendency for higher interleukin 6 levels in the patients (8.5 pg/ml vs. 0.6 pg/ml; \( p = 0.052 \)). No significant differences in serum levels could be found between the three time points.

Conclusion: The present study reveals a characteristic immunological pattern for melanoma patients in comparison to healthy controls. Future studies will have to focus on a putative correlation between immunological markers and clinical outcome parameters.

Highlights

- Malignant melanoma patients reveal a characteristic and distinct immunological pattern.
- Elevated levels of soluble PD-L1 induced by previous immunotherapy were found.
- There were decreased levels of soluble PD-L2 in comparison to healthy controls.

*Correspondence: Michael.oertel@ukmuenster.de

¹ Department of Radiation Oncology, University Hospital Muenster, Albert-Schweitzer-Campus 1, Building A1, 48149 Muenster, Germany

Full list of author information is available at the end of the article
Introduction
Malignant melanoma (MM) is an aggressive skin tumor with rising incidences, the pathophysiology of which is mediated by immunological processes [1–5]. Ipilimumab, an antibody against the cytotoxic t-lymphocyte-associated protein 4 (CTLA-4), a cardinal regulator in the tumor inflammatory micro-milieu, successfully increased overall survival in metastatic patients [4, 5]. Another immunomodulatory protein, programmed-death ligand 1 (PD-L1), is also targeted by a specific antibody [6]. PD-L2 constitutes a further ligand for the PD-receptor [7] which is not addressed by therapeutic antibodies, yet. Likewise, interleukin 6 (IL-6), as an inflammatory mediator, has a complex role in tumor regulation with attributed pro- and anti-neoplastic properties [8].

Recent studies have demonstrated the presence of soluble PD-L1 (sPD-L1) both in vitro and in vivo, which may be measured via an enzyme-linked immunosorbent assay (ELISA) and which has putative prognostic value [9–14].

Soluble markers are advantageous as they are accessible via blood draw and may be used in diagnosis and therapeutic monitoring (liquid biopsy). However, studies on this technique in MM are sparse and often lack patients undergoing RT or detailed information on the dynamic of the parameters. Therefore, the aim of the current analysis was to investigate four important inflammatory parameters (sPD-L1, sPD-L2, IL-6, CTLA-4) in MM patients treated by RT in order to gain insights into their immunological role.

Material and methods
Ethical approval and patient data
The study was designed as a prospective biomarker protocol and approved by our institutional review board (2016-664-f-S with an amendment on 02nd March 2021 for the analysis of PD-L2, CTLA-4 and IL-6) and executed according to the principles of the declaration of Helsinki. Samples from 20 healthy volunteers were received from the institute of transfusion medicine and served as a control group. Written informed consent was given by all patients and volunteers involved.

Patient data on demographics, radiotherapy treatment, toxicities, laboratory values and outcome were collected from the clinical files and the hospital’s information system (Orbis, Dedalus Health Care, Bonn, Germany), which provided toxicity documentation, doctors’ letters and imaging. Follow-up was recorded till April 2022.

Study flow
Blood samples were taken before the beginning of RT (pre-RT), after completion of half of the RT-series (half fractions; mid-RT) and immediately after the completion of RT (post-RT). After collection of 7.5 ml venous blood by sterile venipuncture using a monovette with clotting activator (S-Monovette, Sarstedt, Nümbrecht, Germany), blood samples were stored at room temperature for 30 min to ensure coagulation. Monovettes were then centrifuged for 10 min at 1500×g at room temperature and the supernatant (serum) was transferred and aliquoted into 2 ml cryotubes (Diagonal, Münster, Germany). Serum samples were immediately stored in a freezer at -80 °C until further analysis.

The quantification of the serum parameters PD-L1, PD-L2, CTLA-4 and IL-6 was done using ELISA kits (Bio-Techne, Wiesbaden, Germany) according to the manufacturer’s protocols adapted concerning the optimal serum dilution.

Statistical analysis
Toxicities were graded according to common terminology criteria for adverse events version 5 [15]. Response to treatment was assessed via radiological follow-up.

Statistical analyses were done with SPSS version 28 (IBM, Armonk, New York, USA). Post-hoc power analyses were performed with G’Power version 3.1 (Heinrich-Heine University, Duesseldorf). Progression-free survival (PFS), local control and overall survival (OS) were calculated starting from the first day of RT to the respective event using the Kaplan–Meier method and the log-rank test to compare various factors. Comparisons between the blood level of healthy participants and patients or between the different blood draw dates were done with a two-sample or one-sample t-test, respectively. Categorical variables were compared by means of a two-sided exact Fisher test. A p value < 0.05 was considered as significant.

Results
Overall, 28 patients were recruited to this prospective study with 4 patients being excluded from further analysis (unavailability/poor quality of blood samples, patients not undergoing RT). Details on the study collective are given in Table 1.
After a median follow-up of 30.5 months, 6 patients revealed a local recurrence (mean local control: 44.3 m; 95% confidence interval (CI): 34.7–53.8 m) and overall PFS was 3 m (95% CI: 0–10.9 m).

There was a significant difference in the mean values of PD-L1 (90.1 pg/ml vs. 76.7 pg/ml for patients vs. control, respectively; \( p = 0.024 \); Table 2) and PD-L2 (4.4 ng/ml vs. 8.7 ng/ml; \( p = 0.04 \)) between the baseline serum-level in the patients analyzed and the control collective, respectively (Fig. 1). Patients undergoing previous immunotherapy had a significantly higher PD-L1 level in comparison to patients without (104.0 pg/ml vs. 78.3 pg/ml; \( p = 0.003 \)), which persisted during RT (mid-RT: 107.7 pg/ml vs. 80.2 pg/ml; \( p = 0.007 \); post-RT: 115.4 pg/ml vs. 80.2 pg/ml).

Table 1: Patient and treatment characteristics

| Characteristic                  | n/Median (Range) |
|---------------------------------|------------------|
| Number of patients              | 24               |
| Age at initial diagnosis        | 63.7 y (27.9 y - 78.4 y) |
| Age at RT                       | 67.4 y (29.3 y – 79.3 y) |
| Initial Breslow level           | 3 (1.1–15)       |
| Initial clark stage             |                  |
| 3                               | 1                |
| 4                               | 9                |
| Unknown                         | 14               |
| Stage at initial diagnosis      |                  |
| 1B                              | 2                |
| 2A                              | 2                |
| 2B                              | 1                |
| 2C                              | 4                |
| 3B                              | 6                |
| 3C                              | 2                |
| 4                               | 4                |
| Unknown                         | 3                |
| Stage at RT                     |                  |
| 3B                              | 1                |
| 3C                              | 2                |
| 4                               | 19               |
| Unknown                         | 2                |
| Prior immunotherapy             | 11               |
| Interferon                      | 4                |
| Nivolumab plus ipilimumab       | 4                |
| Nivolumab                       | 3                |
| Concomitant immunotherapy       | 8                |
| Nivolumab                       | 5                |
| Pembrolizumab                   | 2                |
| Nivolumab plus ipilimumab       | 1                |
| RT series                       | 27               |
| Prior RT-series                 | 6                |
| Normofractionated RT-series     | 16               |
| RT-dose                         | 54 Gy (10.8 Gy-66.6 Gy) |
| RT fractionation                | 1.8 Gy (1.8 Gy-2 Gy) |
| Hypofractioned/Stereotactic RT-series |   |
| RT-dose                         | 20 Gy (20 Gy-39 Gy) |
| RT fractionation                | 10 Gy (3 Gy-20 Gy) |
| Toxicities                      |                  |
| Anemia                          | 12 (11 Grade 1, 1 Grade 2) |
| Thrombocytopenia                | 2 (Grade 1)      |
| Lymphopenia                     | 16 (8 Grade 1, 8 Grade 2) |
| Neutropenia                     | 1 (Grade 3)      |
| Mucositis                       | 1 (Grade 3)      |
| Erythema                        | 8 (4 Grade 1, 2 Grade 2, 2 Grade 3) |

\( n = 24 \) with 27 RT series

Gy, gray; RT, radiotherapy; y, year

Table 2: Characterization of the immunological profile (n = 24)

| Parameter               | Patients | Control | \( p \) |
|-------------------------|----------|---------|--------|
| PD-L1                   | 90.1     | 76.7    | 0.024  |
| PD-L2                   | 4.4      | 8.7     | 0.04   |
| IL-6                    | 8.5      | 0.6     | 0.052  |
| CTLA-4                  | 153.7    | 267.2   | 0.295  |

Mean serum levels of inflammatory parameters compared between patients and healthy controls. PD-L1, IL-6 and CTLA-4 in pg/ml; PD-L2 in ng/ml. Significance was tested via two-sample t-tests.

CTLA, cytotoxic t-lymphocyte-associated protein; IL, Interleukin; PD-L, programmed death-ligand

Fig. 1: Box-plot-diagrams displaying the serum levels of PD-L1 (A) and PD-L2 (B) at different time points. Before (pre-RT), after completion of half (mid-RT) and after completion of the radiotherapy (post-RT). In comparison with healthy volunteers, a significant elevation of PD-L1 and decrease of PD-L2 was found (* = significance). RT, radiotherapy
75.3 pg/ml; \( p = 0.011 \)). Increased PD-L1 values prior to therapy were not influenced by the type of immunotherapy (interferon vs. PD-L1 antibody \( p = 0.406 \)). Patients treated with previous interferon uniformly revealed a decrease of PD-L1 in the mid-RT control (compared to pre-RT) which rose again for post-RT. No homogenous behavior for patients treated with PD-L1 antibodies was revealed. In contrast, no significant differences in PD-L1 levels pre-RT were found when patients with previous immunotherapy were excluded (patients: 78.3 pg/ml vs. control: 76.7 pg/ml; \( p = 0.772 \)).

In a post-hoc power analysis the required sample sizes for significant results were estimated: for IL-6 (Cohens d\( = 0.564, \alpha = 0.05 \)) a power of 0.445 resulted in a minimum collective of 25 patients and 21 healthy controls, whereas CTLA-4 (Cohens d\( = 0.321, \alpha = 0.05 \)) required 72 patients and 60 healthy participants.

An elevation of PD-L1 or PD-L2 above the mean or median value did not herald a significant change in distant PFS or overall progression (data not shown).

Overall, 20 out of 24 patients underwent more than one blood draw and were eligible for dynamic investigation: comparisons were made between the blood analysis pre-RT, mid-RT and post-RT, revealing no significant dynamics (Table 3). This did not change when comparing normo- vs. hypofractionation treatments (data not shown). In contrast, when accounting for concomitant immunotherapy there was a significant difference between pre-RT and mid-RT for PD-L1 (84.8 pg/ml vs. 94.0 pg/ml for pre-RT vs. mid-RT; \( p = 0.044 \)) in the group without immunotherapy.

Response assessment was possible for 20 RT series with 9 complete responses and 10 overall responses, both being not influenced significantly by PD-L1 or -2 levels above the mean (\( p = 0.642 \) or 1.0, respectively).

### Table 3

| Parameter | pre-RT | mid-RT | post-RT | \( p \) (pre vs. mid) | \( p \) (pre vs. post) |
|-----------|--------|--------|---------|----------------------|-----------------------|
| PD-L1     | 90.1   | 92.6   | 93.3    | 0.445                | 0.398                 |
| PD-L2     | 4.4    | 5.3    | 6.4     | 0.263                | 0.063                 |
| IL-6      | 8.5    | 8.4    | 9.5     | 0.913                | 0.920                 |
| CTLA-4    | 153.7  | 102.8  | 75.3    | 0.642                | 0.472                 |

Mean serum levels of the respective parameters before (pre-RT), during (mid-RT) and after completion of RT (post-RT) were assessed. PD-L1, IL-6 and CTLA-4 in pg/ml; PD-L2 in ng/ml. Significance of mean values was tested via one-sample t-tests.

CTLA, cytotoxic t-lymphocyte-associated protein; IL, Interleukin; PD-L, programmed death-ligand

### Discussion

The hereby presented analysis outlines a distinctive immunological marker profile for melanoma patients with a decrease in soluble PD-L2 and increase in PD-L1, the latter being induced by previous immunotherapy. This work is one of the first to investigate the expression and dynamics of an immunological marker profile in the context of radiotherapy.

In comparison to healthy volunteers, patients (with melanoma) presented with significantly higher levels of sPD-L1 [12, 14], whereas other works did not describe this difference [13]. The increase may be triggered by previous immunotherapy (as in this work) or circulating inflammatory mediators: Interferon-\( \gamma \), as a pivotal inflammatory cytokine, has been identified at the interface between PD-L1 bearing tumor cells and tumor infiltrating leukocytes and is a potent inducer of sPD-L1 expression both in vitro and in vivo [12, 16].

Data on soluble PD-L2 are sparse and to our knowledge, no decisive analysis in melanoma patients has been conducted. In a population of patients with non-small cell lung cancer treated by nivolumab, sPD-L2 failed to predict response rate, PFS or OS, but was associated with grade 3 and 4 immune related adverse events [17]. In a larger analysis of lymphoma patients encompassing different entities, sPD-L2 was elevated and revealed distinctive levels between different types of diffuse large B-cell lymphoma [18]. In contrast, another work elaborated decreased levels of sPD-L2 in patients with epithelial ovarian cancer [19]. Importantly, the aforementioned investigations report values of sPD-L2 comparable to the numbers described here (1.86–18.25 ng/ml), corroborating validity of our data [17–19].

This analysis has some drawbacks, being mono-institutional and limited in patient number. As all melanoma patients were included, the collective reveals heterogeneity. Due to the anonymization process, the control group of healthy volunteers was not age-matched. Therefore, the results may be pre-liminary and the aim of the examination was rather hypothesis-generating than a proof-of-concept. The set of biomarkers is limited and did not cover important regulators like interferon (s. above). In addition, the level of soluble biomarkers was low being in the range of pg/ml–ng/ml with a considerable variability between different patients (e.g. IL-6 ranged between 0.39 and 93.46 pg/ml). Consequently, Cordonnier and colleagues suggested to use circulating exosomal PD-L1 instead of the soluble version [20]. In the future, a larger and more homogenous patient collective will be attempted. In addition, as there is data illustrating the possible prognostic impact of biomarker changes in the long-term run (e.g. 5 months in [12]), further blood draws shall be attempted.
These implementations will likely shed more light on the dynamics and prognostic implementations of the soluble inflammatory mediators and immunological response in malignant melanoma.

Acknowledgements
Not applicable.

Author contributions
MO, AB, BG and HTE wrote the study protocol. MO, KB and AB conducted biomarker analyses. MO analyzed clinical data and wrote the manuscript. Project supervision was provided by BG and HTE. All authors read and approved the final manuscript.

Funding
Open Access funding enabled and organized by Projekt DEAL. This work was supported by the fund Innovative Medical Research of the University of Münster Medical School (OE 212103).

Availability of data and materials
Not applicable.

Declarations

Ethical approval and consent to participate
The study was designed as a prospective biomarker protocol and approved by our institutional review board (2016-664-F-S with an amendment on 02nd March 2021 for the analysis of PD-L2, CTLA-4 and IL-6) and executed according to the principles of the declaration of Helsinki. Written informed consent was given by all patients and volunteers involved.

Consent for publication
All authors agreed on the final form of the manuscript.

Competing interests
Not applicable.

Author details
1Department of Radiation Oncology, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, 48149 Muenster, Germany. 2Department of Radiation Oncology, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, 48149 Muenster, Germany.

Received: 19 July 2022 Accepted: 21 November 2022
Published online: 28 November 2022

References
1. Erdmann F, Spix C, Katalinic A, Christ M, Folkerts J, Hansmann J, et al. Krebs in Deutschland für 2017/2018. Robert Koch-Institut; 2021 https://edoc.rki.de/handle/176904/9042.
2. Guy GP, Thomas CC, Thompson T, Watson M, Massetti GM, Richardson LC, et al. Vital signs: melanoma incidence and mortality trends and projections—United States, 1982–2030. MMWR Mortal Mortal Wkly Rep. 2015;64:591–6.
3. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkovski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535–46.
4. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.
5. Robert C, Thomas L, Bondarek O, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26.
6. Twyma-Saint Victor C, Rech AJ, Maiti A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373–7.
7. Solinas C, Aiello M, Rozali E, Lambertini M, Willard-Gallo K, Migliori E. Programmed cell death-ligand 2: a neglected but important target in the immune response to cancer? Transl Oncol. 2020;13:100811.
8. Kumari N, Dwaakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance: Tumor Biol. 2016;37:11553–72.
9. Chen Y, Wang Q, Shi B, Xu P, Hu Z, Bai L, et al. Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. Cytokine. 2011;56:231–8.
10. Finkelmeier F, Carli Ö, Tal A, Plei T, Trojan, J, Schmidt M, et al. High levels of the soluble programmed death-ligand (PD-L1) identify hepatocellular carcinoma patients with a poor prognosis. Eur J Cancer. 2016;65:152–9.
11. Takahashi N, Iwasa V, Sasaki Y, Shoji H, Honma Y, Takashima A, et al. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer. J Cancer Res Clin Oncol. 2016;142:1727–38.
12. Zhou J, Mahoney KM, Giobbie-Hurker A, Zhao F, Lee S, Liao X, et al. Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade. Cancer Immunol Res. 2017;5:480–92.
13. Oh SY, Kim S, Keam B, Kim TM, Kim D-W, Heo DS. Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. Sci Rep. 2021;11:19172.
14. Orme JJ, Enninga EAL, Lucien-Matteoni F, Dale H, Burgstaler E, Harrington SM, et al. Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles. J Immunother Cancer. 2020;8:e001113.
15. National Institutes of Health National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Published: November 27, 2017.
16. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMillen TL, et al. Colocalization of inflammatory response by B7–H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012. https://doi.org/10.1126/scitranslmed.3003689.
17. Costantini A, Julie C, Dumend C, Hélias-Rodewicz Z, Zisserand J, Dumoulin J, et al. Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab. Oncoimmunology. 2018;7:e1452581.
18. Mortensen JB, Monrad I, Enemark MB, Ludvigsen M, Kamper P, Bjerr M, et al. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies. Eur J Haematol. 2021;107:81–91.
19. Buderath S, Schwie D, Jensen C, Henn PA, Kimmig R, Kasimir-Bauer S, et al. Soluble programmed death receptor ligands sPD-L1 and sPD-L2 as liquid biopsy markers for prognosis and platinum response in epithelial ovarian cancer. Front Oncol. 2019;9:1015.
20. Cordonnier M, Nardin C, Chanteau P, Darangere V, Algros M-P, Arnold L, et al. Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients. J Extracell Vesicles. 2020;9:1710899.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.